JAGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Jaguar Health Inc (JAGX) is not a strong buy for a beginner investor seeking long-term growth. The stock is exhibiting bearish technical indicators, weak financial performance, and lacks significant positive catalysts or trading signals. It is better to wait for stronger signs of improvement before considering an investment.
The stock is in a bearish trend with MACD negatively expanding, RSI at 24.187 indicating no clear signal, and moving averages showing bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the next support at 0.371.
The company is progressing with its MVID clinical trial, including an extension phase that could potentially secure Breakthrough Therapy designation from the FDA. This may expedite drug approval and improve its market positioning.
The stock experienced significant price declines in pre-market (-7.88%), regular market (-5.62%), and post-market (-0.01%). Financial performance is weak, with declining revenue (-0.80% YoY), net income (-3.57% YoY), and EPS (-76.11% YoY). Technical indicators are bearish, and there are no significant trading trends from hedge funds or insiders.
In Q3 2025, the company reported declining revenue ($3,083,000, down -0.80% YoY), a net loss of -$9,502,000 (down -3.57% YoY), and a significant drop in EPS (-6.28, down -76.11% YoY). However, gross margin slightly increased to 82.74% (+0.18% YoY).
No recent analyst rating or price target changes available.
